← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV20행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTPhase 2
selected dose (ZM-02, ZM-02 (selected dose))
Zhongmou Therapeutics·Retinitis Pigmentosa (RP)
ORR 0%
Overview
Program
ZM-02 (selected dose)
Overview
Company
Zhongmou Therapeutics
Overview
Modality
CGT
Overview
Target
Retinitis Pigmentosa (RP)
Overview
Indication
Retinitis Pigmentosa (RP)
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
MoA
Biomarker
biomarker alterations in vivo
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.. Mu opioid receptor (MOR) analgesics like morphine have high intrinsic MOR efficacy but produce side effects. Lower efficacy MOR agonists like buprenorphine can produce analgesia with improved safety. We recently described a series of novel phenylmorphan-based MOR agoni…
Toxicology
CRS
59.5%
Clinical
ORR
0%
Clinical
Result source
ClinicalTrials.gov NCT02528357
Clinical
Data Tier / Score
A · 34
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 13일 (1일 전)